Início › Leucemia Mieloide Aguda › Connecticut
Ensaios clínicos de Leucemia Mieloide Aguda em Connecticut
17 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Connecticut.
Cidades em Connecticut
Texto oficial do estudo (Inglês)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Yale University, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
RecrutandoFase 2
Idades de 18 a 59 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
RecrutandoFase 3
6 Months – 21 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Yale University, New Haven
RecrutandoFase 3
29 Days – 21 Years · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Yale University, Yale Cancer Center, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06656494A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Yale New Haven Hospital, New Haven
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Yale New Haven Hospital, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 15 de jun. de 2026 · NCT05768932A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de abr. de 2026 · NCT04256317Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
RecrutandoFase 1
Idades de 18 a 75 · Todos os sexos · Atualizado em 25 de mar. de 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT05735184Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Yale University, New Haven
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2025 · NCT03850574Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.